Cassava Sciences, Inc.

SAVA | NASDAQ | 16 Followers
$2.15 -1.83% -$0.04
Follow
Overview Metrics Financials
Loading...

Fair Price

$4.75
Overvalued by 90.2%
To display the fair price of a share, you need to be a member of Bulios Black.

Profile

Cassava Sciences, Inc. (SAVA) is a biotechnology company focused on research and development of therapeutic treatments for neurodegenerative diseases. The company's primary goal is to discover innovative therapies targeting Alzheimer's disease, one of the most devastating cognitive impairing illnesses. Cassava Sciences is developing a drug known as Simufilam, which has undergone clinical trials and has shown promising results in improving cognitive functions in Alzheimer's disease patients. Investing in Cassava Sciences' stock may present an attractive opportunity for investors who closely follow advancements in neurodegenerative disease treatments and seek innovative companies with potential in the biotechnology field.

Feed

>3y
Read More

Le azioni di Cassava Sciences $SAVA sono attualmente scambiate a soli 26,77 dollari per azione. L'azienda sta mostrando segni molto importanti nello sviluppo di farmaci per il morbo di Alzheimer che si stanno avvicinando alla fase clinica finale (3) di sviluppo. Appena in ritardo nel 2021, l'azienda ha visto il successo basato su un'impennata di popolarità degli investitori...
Read more
0
Share
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade